key: cord-1019227-z7ag36pl authors: Qamar, Naila; Rukh, Gul; Khan, Sadiq N. title: Vaccines for Covid‐19: An insight on their effectiveness and adverse effects date: 2022-05-05 journal: J Med Virol DOI: 10.1002/jmv.27810 sha: 2c2f3877fdb86732f7a02eb8f0016c589f0a124a doc_id: 1019227 cord_uid: z7ag36pl An era of SARS‐COVID‐19 outbreak with a high contagious percentage around the globe has been the subject of multi‐agency research aimed at generating vaccines for active immunization. Scientists across the world are joining hands for advanced tie‐ups between medical start‐ups and pharmaceutical industries for devices and vaccines development to hinder the progress of this outbreak. Moreover, the questions that need to be answered are how to improve the effectiveness and efficacy of vaccines with reduced side effects and the required doses of vaccines for enhanced surveillance. In this review article, we have discussed the effectiveness and efficacy of different Covid‐19 vaccines. | 1 times more than that of Germany. 4, 15 So, developing an effective vaccine against this SARS-COVID-19 is an important step and the only way of establishing herd immunity. 4 The most therapeutic drugs for SARS-Covid-19 cases and the effective vaccines for the people were urgent needs. As there is no specific drug to treat SARS-COVID-19 worldwide but the four vaccines that is, COVID-19 messenger RNA (mRNA) vaccine BNT162b2 (Pfizer), mRNA-1273 vaccine (Moderna), ChAdOx1 nCoV-19 vaccine/AZD1222 (AstraZeneca), and Sinovac that have low safety risk and higher efficacies of 95%, 94.1%, 70.4%, and 78%, respectively were used in many countries. 16, 17 The Oxford AstraZeneca, Johnson and Johnson, and Sputnik vaccines use engineered live viral vectors to demonstrate the coronavirus spike protein, while the vaccines developed by Pfizer and Moderna make use of recent technology, such as messenger RNA. 4, 18 In general, China's coronavirus vaccines may need to be replaced or administered differently to be successful resist the SARS-Cov2 virus, according to the head of China's Center for Disease Prevention and Control. 18 The vaccine efficacy is assessed by using the relative risk (RR) method, the relation of COVID-19 attack rates with and without a COVID-19 vaccine which is stated as 1-RR. The effectiveness of the vaccine was assessed by using the cohort study design which compared the incidence in the general cohort of persons with the incidence of COVID-19 infection in the vaccinated persons who were antibody negative. 19 The AstraZeneca is a monovalent vaccine comprised of a single recombinant, adenoviral vector (the icosahedral virions, nonencapsulated with a single linear molecule of DNA) encoding the S glycoprotein of Covid-19. 22, 23 Furthermore, the AstraZeneca vaccine also contains polysorbate 80, disodium edetate dihydrate, magnesium chloride hexahydrate, sucrose, L-histidine hydrochloride monohydrate, Lhistidine, sodium chloride, ethanol, and water for injection. The efficacy of the AstraZeneca Vaccine was 63.09% (95% confidence interval). 22, 37 The time of vaccine opening to administration requires 2-8°C temperature due to the small shelf-life of vaccines which is 6 months. 38 The vaccine developed by AstraZeneca, a British-Swedish company, has been a source of considerable promise. 39 The Oxford AstraZeneca vaccination is inexpensive and may be stored in a regular refrigerator because it is projected to be manufactured in large quantities, it could be significant in limiting the pandemic. 40, 41 For the time being, "the AstraZeneca vaccine is the only one that will be available in considerable quantities in many places, particularly on the African continent." 40 The vaccine shows some adverse reaction which is mild to moderate in some cases. Most adverse reactions were reported after the second dose such as injection site pain, headache, injection site tenderness, fatigue, malaise, myalgia, arthralgia, and nausea. 23 The Oxford AstraZeneca COVID-19 vaccine has a low level of perceived safety, particularly among vaccine skeptics. 42 Some European governments banned the use of the AstraZeneca vaccination on March 15, 2021, as a precautionary measure following the deaths of a few hundred patients who developed blood clots because of deep vein thrombosis. 43 Tenderness, discomfort, warmth, redness, itching, inflammation, and blisters at the injection site are common Indian AstraZeneca adverse effects. 44 Recent studies of thrombocytopenia-related cerebral venous sinus thrombosis, repeated thrombosis, and hemorrhage occurring within a short time after receiving the vaccination are alarming, and health officials are paying close attention. Multiple thrombosis, bleeding, and thrombocytopenia, all of which seem to be symptoms of disseminated intravascular coagulation. 45 SinoVac, was found to be 50.4% effective in late-stage trials in preventing severe and mild COVID-19. This is far less than the 90% efficacy of several popular vaccines. 40 The adverse reactions which was reported during the Sinovac trial is fatigue, fever, muscle pain, anorexia, muscle distention, acute allergic reaction, and diarrhea. 29 , 10 The Pfizer-BioNTech BNT162b2 is a messenger RNA vaccine that shows 95% efficacy against SARS-COVID-19. 19, 51 The Pfizer-vaccine is composed of ALC-0315, potassium chloride, cholesterol, sodium chloride, disodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate sucrose, and water for injection. 52 The effectiveness of the Pfizer vaccine was assessed by using a cohort study design in which they measure the effectiveness of the vaccine by comparing the incidence in the general cohort of persons with the incidence of COVID-19 infection in the vaccinated persons who were antibody negative. 19, 53 The Pfizer vaccine effectiveness in the B117 variant was 89.5% and the B1351 variant was 75.0% at 14 days after the second dose. 19 In May, its Phase 2 trial was introduced on two varieties of the vaccine 54 70, 71 The effectiveness of the vaccine was calculated after prime immunization with two dosages of ChAdOx1 nCoV-19 (AstraZeneca), BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) vaccine. The investigations for all combinations of primary dosages of vaccines were found to be highly effective against the delta variant than the omicron. While the partial protection was provided against the omicron variant by the prime immunization with two dosages of BNT162b2 or ChAdOx1 nCoV-19 vaccine. 71 Development of a vaccine is a laborious process with many stages, that is, the preclinical and clinical stages, etc hence, the novel approaches to COVID-19 have therefore enforced the research community to adopt unconventional methods to accelerate the process of vaccine development. Researchers used a Cohort Study design to measure the effectiveness of the vaccine by comparing the incidence in the general cohort of persons with the incidence of COVID-19 infection in the vaccinated persons who were antibody negative. The need of the hour is to develop an effective and safe vaccine against COVID-19 with enhanced efficacy and reduced side effects. No funding was received from any commercial or public sector organizations to carry out this study work. The authors declare no conflicts of interest. This manuscript has no associated data to make it available. ORCID Naila Qamar http://orcid.org/0000-0002-3593-4618 The COVID-19 epidemic MERS-CoV outbreak in Jeddah-a link to health care facilities COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room A review of the progress and challenges of developing a vaccine for COVID-19 Estimation of COVID-19 prevalence in Italy, Spain, and France Real-time tracking of selfreported symptoms to predict potential COVID-19 Geographical structure of bat SARSrelated coronaviruses COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses How can airborne transmission of COVID-19 indoors be minimised? COVID-19 vaccination efficacy and safety literature review A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention COVID-19 vaccine safety BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers Herd immunity: understanding COVID-19 Herd immunity or suppression strategy to combat COVID-19 COVID-19: coronavirus vaccine development updates COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations Covid-19: Chinese vaccines may need changes to improve efficacy, admits official Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B Mortality rate and characteristics of deaths following COVID-19 vaccination COVID-19 'Vaccine for the World' shows up to 90% efficacy Organization WH Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca: background document to the WHO Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca Evaluation of the immunogenicity of prime-boost vaccination with the replicationdeficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 The Oxford/AstraZeneca COVID-19 vaccine: what you need to know. World Health Organization Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants. medRxiv Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates EMA receives application for conditional marketing authorisation of COVID-19 vaccine Janssen Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial Three-quarters attack rate of SARS-CoV-2 in the Brazilian amazon during a largely unmitigated epidemic Review on up-to-date status of candidate vaccines for COVID-19 disease Neutralization of SARS-CoV-2 VOC 501Y. V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines China's CanSino covid vaccine shows 65.7% efficacy Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet Covaxin efficacy 78% in phase 3 analysis; 2021. 36. health-canada GoC. Novavax Nuvaxovid COVID-19 vaccine World Health Organization. The Oxford/AstraZeneca COVID-19 vaccine Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial. The Lancet New problems erode confidence in AstraZeneca's vaccine What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine Covid-19: new data on Oxford AstraZeneca vaccine backs 12 week dosing interval Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? The Lancet Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 The Sinovac COVID-19 vaccine; 2021. 48. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19.30 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial What do we know about China's covid-19 vaccines? Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review Coronavirus vaccine tracker Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Moderna covid-19 vaccine to prevent coronavirus disease 2019 (covid-19) in individuals 18 years of age and older Moderna COVID-19 vaccine COVID-19 Vaccine: a comprehensive status report COVID arm": a reaction to the Moderna vaccine COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet COVID-19 vaccineassociated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, nonrandomised phase 1/2 studies from Russia. The Lancet The COVID-19 pandemic in children and young people during 2020-2021: a complex discussion on vaccination Should children be vaccinated against COVID-19? Interim statement on COVID-19 vaccination for children and adolescents COVID-19 vaccine information for children (ages five to 11) mRNA Covid-19 vaccines in pregnancy: a systematic review Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy BNT162b2 vaccine booster and mortality due to Covid-19 Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant Covid-19 vaccine effectiveness against the omicron (B. 1.1. 529) variant